Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16058-

  Dasari, Vijayendra ^a   Schuessler, Andrea ^a   Smith, Corey ^a   Wong, Yide ^a,b   Miles, John J ^a,b   Smyth, Mark J ^a,e   Ambalathingal, George ^a   Francis, Ross ^c,e   Campbell, Scott ^c   Chambers, Daniel ^d,e   Khanna, Rajiv ^a,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Human Immunity Laboratory   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; EPITOPE; EVEROLIMUS; GANCICLOVIR; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; T LYMPHOCYTE ANTIGEN; TACROLIMUS; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR;

ADENOVIRIDAE; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BK VIRUS; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; ADOPTIVE TRANSFER; ADULT; ANIMAL MODEL; CANCER SURVIVAL; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOGENICITY; LYMPHOCYTE TRANSFER;

EID: 85015205697     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.58     Document Type: Article

References (38)

1. 1 Fishman, JA, Issa, NC, Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 24 (2010), 273–283.
2. 2 Gratwohl, A, Brand, R, Frassoni, F, Rocha, V, Niederwieser, D, Reusser, P, et al., Acute and Chronic Leukemia Working Parties; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation, Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36 (2005), 757–769.
3. 3 Green, M, Introduction: Infections in solid organ transplantation. Am J Transplant 13:Suppl 4 (2013), 3–8.
4. 4 Humar, A, Kumar, D, Preiksaitis, J, Boivin, G, Siegal, D, Fenton, J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 5 (2005), 1462–1468.
5. 5 Humar, A, Lebranchu, Y, Vincenti, F, Blumberg, EA, Punch, JD, Limaye, AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10 (2010), 1228–1237.
6. 6 Humar, A, Limaye, AP, Blumberg, EA, Hauser, IA, Vincenti, F, Jardine, AG, et al. Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplant 90 (2010), 1427–1431.
7. 7 Biron, KK, Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71 (2006), 154–163.
8. 8 Boeckh, M, Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1 (1999), 165–178.
9. 9 Boeckh, M, Zaia, JA, Jung, D, Skettino, S, Chauncey, TR, Bowden, RA, A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 4 (1998), 13–19.
10. 10 Hill, GR, Tey, SK, Beagley, L, Crough, T, Morton, JA, Clouston, AD, et al. Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient. Am J Transplant 10 (2010), 173–179.
11. 11 Holmes-Liew, CL, Holmes, M, Beagley, L, Hopkins, P, Chambers, D, Smith, C, et al. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology, 4, 2015, e35.
12. 12 Khanna, R, Smith, C, Cellular immune therapy for viral infections in transplant patients. Indian J Med Res 138 (2013), 796–807.
13. 13 Heslop, HE, Leen, AM, T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program 2013 (2013), 342–347.
14. 14 Kaloyannidis, P, Leen, AM, Papadopoulou, A, T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation. Expert Rev Hematol 5 (2012), 471–473.
15. 15 Tzannou, I, Leen, AM, Preventing stem cell transplantation-associated viral infections using T-cell therapy. Immunotherapy 7 (2015), 793–810.
16. 16 Leen, AM, Bollard, CM, Mendizabal, AM, Shpall, EJ, Szabolcs, P, Antin, JH, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121 (2013), 5113–5123.
17. 17 Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12 (2006), 1160–1166.
18. 18 Melenhorst, JJ, Castillo, P, Hanley, PJ, Keller, MD, Krance, RA, Margolin, J, et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther 23 (2015), 179–183.
19. 19 Gerdemann, U, Keirnan, JM, Katari, UL, Yanagisawa, R, Christin, AS, Huye, LE, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20 (2012), 1622–1632.
20. 20 Gerdemann, U, Vera, JF, Rooney, CM, Leen, AM, Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. JoVE, 51, 2011, 2736 10.3791/2736.
21. 21 Smith, C, Økern, G, Rehan, S, Beagley, L, Lee, SK, Aarvak, T, et al. Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. Clin Transl Immunology, 4, 2015, e31.
22. 22 Bollard, CM, Gottschalk, S, Torrano, V, Diouf, O, Ku, S, Hazrat, Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32 (2014), 798–808.
23. 23 Bollard, CM, Rooney, CM, Heslop, HE, T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9 (2012), 510–519.
24. 24 Fuji, S, Kapp, M, Grigoleit, GU, Einsele, H, Adoptive immunotherapy with virus-specific T cells. Best Pract Res Clin Haematol 24 (2011), 413–419.
25. 25 Fernández-Ruiz, M, Kumar, D, Humar, A, Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol, 3, 2014, e12.
26. 26 Westervelt, JD, Alexander, BD, Costa, SF, Miller, SE, Howell, DN, Smith, SR, Detection of BK polyomavirus after kidney transplantation: a comparison of urine electron microscopy with plasma polymerase chain reaction. Clin Transplant 27 (2013), E42–E48.
27. 27 Ljungman, P, Hakki, M, Boeckh, M, Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 25 (2011), 151–169.
28. 28 Gerna, G, Lilleri, D, Furione, M, Baldanti, F, Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. New Microbiol 34 (2011), 229–254.
29. 29 Gerdemann, U, Katari, UL, Papadopoulou, A, Keirnan, JM, Craddock, JA, Liu, H, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21 (2013), 2113–2121.
30. 30 Papadopoulou, A, Gerdemann, U, Katari, UL, Tzannou, I, Liu, H, Martinez, C, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med, 6, 2014, 242ra83.
31. 31 Krause, PR, Bialek, SR, Boppana, SB, Griffiths, PD, Laughlin, CA, Ljungman, P, et al. Priorities for CMV vaccine development. Vaccine 32 (2013), 4–10.
32. 32 Schleiss, MR, VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther 11 (2009), 572–578.
33. 33 Wang, Z, Zhou, W, Srivastava, T, La Rosa, C, Mandarino, A, Forman, SJ, et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virol 377 (2008), 379–390.
34. 34 Zhong, J, Khanna, R, Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 5 (2007), 449–459.
35. 35 Elkington, R, Walker, S, Crough, T, Menzies, M, Tellam, J, Bharadwaj, M, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77 (2003), 5226–5240.
36. 36 Gandhi, MK, Khanna, R, Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4 (2004), 725–738.
37. 37 Hislop, AD, Taylor, GS, Sauce, D, Rickinson, AB, Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25 (2007), 587–617.
38. 38 Leen, AM, Christin, A, Khalil, M, Weiss, H, Gee, AP, Brenner, MK, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82 (2008), 546–554.